Renal Blood Flow Measurement With Positron Emission Tomography (PET)
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Nephrology |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | August 2008 |
| End Date: | April 2009 |
| Contact: | Jeffrey L Lacy, PhD |
| Email: | jlacy@proportionaltech.com |
| Phone: | 713-747-7324 |
Renal Blood Flow Measurement With PET
Two investigational chemical tracers, 62Cu-ethylglyoxal bis(thiosemicarbazone) (62Cu-ETS)
and 15O-water, will be used in this study to look at how blood moves through the kidneys.
The purpose of the study is to see if 62Cu-ETS is effective in showing the blood supply to
the kidneys compared to 15O-water. The tracer mixes with the blood and moves through the
body. Using positron emission tomography (PET scan) the researchers can see the tracer and
can learn more about how the blood moves through the kidneys. The study invites participants
who are healthy, without any heart or kidney disease, patients who have kidney disease that
require dialysis, and patients who may have a blockage in one of the arteries supplying
blood to the kidneys.
and 15O-water, will be used in this study to look at how blood moves through the kidneys.
The purpose of the study is to see if 62Cu-ETS is effective in showing the blood supply to
the kidneys compared to 15O-water. The tracer mixes with the blood and moves through the
body. Using positron emission tomography (PET scan) the researchers can see the tracer and
can learn more about how the blood moves through the kidneys. The study invites participants
who are healthy, without any heart or kidney disease, patients who have kidney disease that
require dialysis, and patients who may have a blockage in one of the arteries supplying
blood to the kidneys.
Arm 1.
Inclusion Criteria:
- males and females, age 18-40 years
- willingness to provide written informed consent
Exclusion Criteria:
- history of coronary artery disease (CAD)
- history of renal disease
- risk factors for cardiac disease, renal disease, or atherosclerosis, including
diabetes mellitus, hypertension, tobacco abuse, hyperlipidemia, family history of CAD
or chronic renal failure
- history of liver disease or other significant disease
- pregnant females
Arm 2.
Inclusion Criteria:
- males and females, age > 18 years
- active hemodialysis or peritoneal dialysis for at least six months
- any etiology of chronic renal failure except active glomerular nephritis
- presence of two kidneys
- willingness to provide written informed consent
Exclusion Criteria:
- decompensated heart failure (subjects must be on stable medical therapy for one
month)
- any previous renal transplant (subjects may be on renal transplant waiting list)
- history of liver disease
- pregnant females
Arm 3.
Inclusion Criteria:
- males and females, age > 18 years
- documented evidence of renal artery stenosis equivalent to a 75% stenosis by one of
the following clinical tests: MRA, Doppler, Renal Angiogram, Abnormal captopril renal
scan
- evidence of renal insufficiency with serum creatinine >= 1.3 mg/dL
- presence of two kidneys
- willingness to provide written informed consent
Exclusion Criteria:
- revascularization of stenotic renal artery
- decompensated heart failure (subjects must be on stable medical therapy for one
month)
- any previous renal transplant (subjects may be on renal transplant waiting list)
- history of liver disease
- pregnant females
We found this trial at
1
site
University of Wisconsin-Madison In achievement and prestige, the University of Wisconsin-Madison has long been recognized...
Click here to add this to my saved trials
